Abstract: This invention relates to a method for forming a three dimensional sintered body comprising the steps of a) providing a basic mould having a configuration adapted to the sintered body that is to be produced, b) treating the surface of the basic mould to facilitate application of a first surface layer of the sintered body, c) applying powder particles onto the basic mould, to form said first surface layer, d) applying at least one more layer on top of said first surface layer, e) heat treating the basic mould and the particles to form a sintered body, wherein step b) is performed by providing an adhering layer to the basic mould arranged to adhere the particles of at least a portion of the surface layer.

Abstract: This invention relates to a method for forming a three dimensional sintered body (100) comprising the steps of a) providing a basic mould having a configuration adapted to the sintering body that is to be produced, b) treating the surface of the basic mould to facilitate application of a first surface layer (130) of the sintered body (100), c) applying powder particles (131) onto the basic mould, to form said first surface layer (130), d) applying at least one more layer (120) on top of said first surface layer (130), e) heat treating the basic mould (400) and the particles to form a sintered body, wherein step b) is performed by providing an adhering (604) to the basic mould arranged to adhere the particles (131) of at least a portion of the surface layer (130).

Abstract: The present invention relates to a tank assembly for making fibre products from stock comprising a stock vat, a main tank (2, 103, 202), at least one inlet (20, 21, 111, 216) to said main tank from said stock vat, and an outlet (22, 113, 217) from said main tank. The tank assembly further comprises at least one mould tank (3, 102, 203, 204) having at least one inlet (37, 114, 218, 219) at its bottom connected to the inlet to said main tank and an outlet (4, 116, 221, 223) connected to said main tank so that stock from the mould tank is arranged to flow into said main tank and in that the horizontal cross-sectional area at the top of said mould tank is larger than the horizontal cross-sectional area at the bottom of said mould tank.

Abstract: The present invention relates to an electronic shelf label, a system including electronic shelf labels, a related method and a computer program, comprising a power source for giving power to a display for displaying product related information, and at least one memory register for storing a product related information, and a communication interface for communicating with an access communication unit from which commands are exchanged, the memory register and the communication interface being controlled by a control unit. The control unit is adapted to control the display of information from the register in dependence of received commands and the invention is characterised in that the electronic shelf label is provided, in addition to the a display for displaying product related information, with an additional display of information.

Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as

Abstract: An electronic label showing information about a product related to this electronic label on a display (9; 31), said electronic label being updated from a central control unit. According to the invention the electronic label comprises a replaceable front shell (5; 21) and a stationary communication part (3; 23) to which the front shell should be attached.

Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R4)(R5)]xN(R2a)(R3a)]; R2a, R3a, R4, R5, R6 and x are as

Abstract: The invention relates to compounds of the general formula (I): wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO2—, —NH—, (ii) a C1-4-alkyl- or C1-6-acyl-substituted nitrogen atom or (iii) a C1-8-alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R4)(R5)—, —OC(R4)(R5)—, —N(R6)C(R4)(R5)—, —N(R6)—, —O—, —S— or —SO2—; R is optionally substituted C3-8-cycloalkyl, aryl or heteroaryl; R1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ri

Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.

Abstract: Substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) were isolated from plasma and characterized. Apolipoprotein AI-M dimer can also be produced in a recombinant Escherichia coli system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are described. Patients with atherosclerosis or cardiovascular diseases can be treated with the dimer. Medicaments containing the dimer can also be used to prevent thrombosis in different clinical circumstances, both at the arterial and at the venous level. The dimer can also act as a prodrug for the monomer.

Abstract: Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.

Abstract: Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2 receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2c receptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.